Abstract:Previous studies have reported the stepwise nature of human immunodeficiency virus type 1 (HIV-1) entry and the pivotal role of coreceptor CCR5 and the gp41 N-terminal heptad repeat (NHR) region in this event. With this in mind, we herein report a dual-targeted drug compound featuring bifunctional entry inhibitors, consisting of a piperidine-4-carboxamide-based CCR5 antagonist, TAK-220, and a gp41 NHR-targeting fusion-inhibitory peptide, C34. The resultant chimeras were constructed by linking both pharmacophores with a polyethylene glycol spacer. One chimera, CP12TAK, exhibited exceptionally potent antiviral activity, about 40- and 306-fold over that of its parent inhibitors, C34 and TAK-220, respectively. In addition to R5-tropic viruses, CP12TAK also strongly inhibited infection of X4-tropic HIV-1 strains. These data are promising for the further development of CP12TAK as a new anti-HIV-1 drug. Results show that this strategy could be extended to the design of therapies against infection of other enveloped viruses.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00781?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00781</a>.HPLC method used for the purification of peptide compounds; HPLC method used for the analysis of peptide compounds; potential cytotoxicity of CP12TAK on CEMx174 5.25M7 and MT-2 cells; MALDI-TOF-MS and Analytical HPLC of designed peptides; <sup>1</sup>H and <sup>13</sup>C NMR spectra of small-molecule compounds; and ESI-TOF-MS spectra of small-molecule compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00781/suppl_file/jm1c00781_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00781/suppl_file/jm1c00781_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor.

Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF Association.

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Small organic molecules targeting PCAF bromodomain as potent inhibitors of HIV-1 replication

Design of Tat-Activated Cdk9 Inhibitor

HIV-1 Transcription Inhibition Using Small RNA-Binding Molecules.

Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity.

The TAR Binding Dynamics and Its Implication in Tat Degradation Mechanism

Virtual Screening, Biological Evaluation, And 3d-Qsar Studies Of New Hiv-1 Entry Inhibitors That Function Via The Cd4 Primary Receptor

Structure-Based Identification of Small Molecule Antiviral Compounds Targeted to the Gp41 Core Structure of the Human Immunodeficiency Virus Type 1

Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association.

Co-crystal structures of HIV TAR RNA bound to lab-evolved proteins show key roles for arginine relevant to the design of cyclic peptide TAR inhibitors

A Computational Study of Tat-CDK9-Cyclin Binding Dynamics and Its Implication in Transcription-Dependent HIV Latency.

Computational identification and analysis of CNP0269688 as a natural product inhibitor disrupting the interaction between the HIV matrix domain and tRNA

Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-[1,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives

Identifying the Molecular Mechanics and Binding Dynamics Characteristics of Potent Inhibitors to HIV‐1 Protease

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure

Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors

Aqueous solution structure of a hybrid lentiviral Tat peptide and a model of its interaction with HIV-1 TAR RNA

Insights into the Structural Function of the Complex of HIV-1 Protease with TMC-126: Molecular Dynamics Simulations and Free-Energy Calculations